B+
Bull case
20%
Probability
Target price
$14.00
Analysis reference price unavailable
Analysis 2026-07-31 · RankAlpha Sentiment Codex
PHAR
Pharming GroupBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$11.50
Analysis reference price unavailable
Analysis 2026-07-31 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$8.75
Analysis reference price unavailable
Analysis 2026-07-31 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-07-31
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+63.9
Score
AI commentary
Post-earnings tone is mixed-to-negative: strong Joenja growth and pipeline catalysts were outweighed near term by the revenue-guidance cut, lower operating profit, and an approximately 11.6% decline versus the prior close. Analyst revisions and social coverage were unavailable, so missing external confirmation is not treated as positive evidence.
RankAlpha Sentiment Codex - 2026-07-31
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-07catalystPost-earnings guidance reset digestionMedium impact
Pharming cut 2026 revenue guidance to US$375m-US$395m from US$405m-US$425m; Q2 operating profit also fell to US$1.3m from US$10.8m. The latest quote was US$10.75, down 11.6% from the prior close, leaving near-term estimate-reset risk elevated [#PR-2026-07-30].
2026-10-24eventFDA decision on pediatric Joenja label expansionHigh impact
The FDA accepted Pharming’s resubmitted sNDA for Joenja in children aged 4-11 and assigned an October 24, 2026 PDUFA date. Approval would expand the addressable APDS population, but follows a January CRL [#PR-2026-06-04] [#PR-2026-07-30].
2027-07-31catalystCVID and broader PID Phase II readoutsHigh impact
Two leniolisib Phase II trials in broader primary immunodeficiencies, including CVID, have completed enrollment, with top-line readouts expected in Q4 2026. Positive data could materially expand the commercial opportunity beyond APDS [#PR-2026-07-30].
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-31 • Updated nightlySource: Internal modelMethodology